A Phase 2 interventional study of Triheptanoin in GLUT1DS1, sponsored by University of Texas Southwestern Medical Center. Completed at 1 site in United States. Open to participants aged 30 Months to 35 Years. Per ClinicalTrials.gov, last updated 2024-01-17.
Sponsored by University of Texas Southwestern Medical Center · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To explore triheptanoin (C7 oil) compatibility with the ketogenic diet by evaluating EEG, and seizure rate, glycemia and ketosis in proven G1D patients receiving a ketogenic diet.
This is a single site, open label proof of principle exploratory trial to investigate the compatibility of C7 oil with the ketogenic diet in subjects diagnosed with G1D. The ketogenic diet will have been previously described by the patient's treating physician independently of this study and for clinical reasons. The ketogenic diet supplies over 50% of calories from fat, subjects, who are already tolerating over this much fat as part of their previously prescribed ketogenic diet, will replace 45% of their daily caloric intake with the triheptanoin for 24 hours, during a 48 hour inpatient stay. Subjects will have a continuous EEG to monitor for any potential C7 related changes in seizure before, during, and after triheptanoin oil ingestion.
University of Texas Southwestern Medical Center is the lead sponsor of 1,012 studies on the registry; 200 are open to participants now.
Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is a one arm study were patients will be receiving an oil called triheptanoin. Patients will be consuming triheptanoin 4 times over the course of one day. The triheptanoin oil will take up 45% of their daily calories on the day the day they are taking the oil.
Drug: Triheptanoin
Dietary supplementation with triheptanoin
Also known as: C7 oil
Change in Ketosis (Beta-hydroxybutyrate Levels)
Change in Ketosis as measured by changes in blood beta-hydroxybutyric acid levels.
Time frame: Day 1, Day 4
Fraction of Subjects (of a Total of 10 Studied) Who Exhibit a Change in Observable Seizure Rate
The percent change in observable seizure rate is measured as the change in observable seizure numbers from baseline to Day 4. Seizure rate is defined as count of seizures per patient per day.
Time frame: Baseline (Day 1) - Day 4
Change in Glycemia
Change in Glycemia is measured as changes in blood glucose levels.
Time frame: Day 1 - Day 4
| Milestone | Experimental: Triheptanoin (C7) |
|---|---|
| Started | 10 |
| Completed | 10 |
| Not completed | 0 |
Change in Ketosis as measured by changes in blood beta-hydroxybutyric acid levels.
| mM | Ketosis |
|---|---|
| Change in Ketosis (Beta-hydroxybutyrate Levels) | 3.82 ± 1.9 |
The percent change in observable seizure rate is measured as the change in observable seizure numbers from baseline to Day 4. Seizure rate is defined as count of seizures per patient per day.
| Participants | Fraction of Subjects With a Change in Seizure Rate |
|---|---|
| Fraction of Subjects (of a Total of 10 Studied) Who Exhibit a Change in Observable Seizure Rate | 3 |
Change in Glycemia is measured as changes in blood glucose levels.
| mg/dl | Glycemia |
|---|---|
| Change in Glycemia | 81.2 ± 13.6 |
Collected over Days 1 - 4. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ketosis | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| Event | Ketosis |
|---|---|
| SeizuresNervous system disorders | 2/10 |
| Age, Categorical(Participants) | Triheptanoin (C7 Oil, Liquid) |
|---|---|
| <=18 years | 9 |
| Between 18 and 65 years | 1 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | Triheptanoin (C7 Oil, Liquid) |
|---|---|
| Female | 6 |
| Male | 4 |
| Ethnicity (NIH/OMB)(Participants) | Triheptanoin (C7 Oil, Liquid) |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 9 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Triheptanoin (C7 Oil, Liquid) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 9 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Triheptanoin (C7 Oil, Liquid) |
|---|---|
| United States | 9 |
| Argentina | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2018 to primary completion in Jun 2021, 36 months.
Results were first posted in Jan 2024, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Triheptanoin
University of Texas Southwestern Medical Center →